An official website of the United States government
The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. The NIH has standardized the Exploratory/Developmental Grant (R21) application characteristics, requirements, preparation, and review procedures in order to accommodate investigator-initiated (unsolicited) grant applications.
PA-20-194 Contacts and Special Interests
Release Date: May 16, 2020
Expiration Date: May 08, 2024
R21 Clinical Trial Required Participating Institutes and Centers
- NIH Institutes and Centers that accept Investigator-Initiated R21 applications in response to the Parent R21 Clinical Trial Required Announcement - (PA-19-054): NHGRI, NIA, NIAAA, NIAID, NIDA, NIDCD, NIEHS, NIMHD, NINR, NICHD
- NIH Institutes and Centers that only accept Investigator-Initiated R21 applications proposing mechanistic clinical trials in response to the Parent R21 Clinical Trial Required Announcement PA-19-054): NIAMS ,NIMH
- NIH Institutes and Centers that DO NOT ACCEPT applications in response to the Parent R21 Clinical Trial Required Announcement but ONLY accept R21 applications proposing clinical trial(s) in response to their specific funding opportunity announcements: : NCI, NHLBI, NIBIB, NICHD, NIDCR, NIDDK, NIGMS, NINDS, NLM, FIC, NCCIH, NCATS
| NIH Institute/Center | Scientific/Research Contact Scientific Research Areas of Interest | Financial of Grants Management Contact |
|---|---|---|
| National Human Genome Research Institute (NHGRI) | Jennifer Troyer, Ph.D. Telephone: 301-312-3276 Email: [email protected] NHGRI’ specific scientific interest statement: NHGRI will support the development of resources, approaches, and technologies that will accelerate GENOMIC research on the structure of genomes, the biology of genomes, and the biology of disease; that will advance the science of genomic medicine; and that will incorporate genomics to improve the effectiveness of healthcare. NHGRI will also support GENOMIC research in several cross-cutting areas, including the ethical, legal and societal implications of genomics and genetics research, bioinformatics, technology development, and research training and career development. In general, NHGRI supports studies that provide generalizable methods and knowledge. Applications for studies relevant only to a particular disease or organ system should be directed to the appropriate Institute or Center. NHGRI strongly encourages potential applicants to contact program staff in the early stages of developing your application. The contact information for the three scientific programs are: Division of Genome Science: https://www.genome.gov/27550609/division-of-genome-sciences-staff/ Division of Genomic Medicine: https://www.genome.gov/27550610/division-of-genomic-medicine-staff/ Division of Genomics and Society: https://www.genome.gov/27550080/division-of-genomics-and-society/ |
Deanna L. Ingersoll Telephone: 301-435-7858 Email: [email protected] |
| National Institute on Aging (NIA) | Dr. Sally Marik Division of Extramural Activities Telephone: 301- 594-2360 Email: [email protected] |
Ms. Traci Lafferty Telephone: 301-496-1472 Email: [email protected] |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Division of Epidemiology and Prevention Research Gregory Bloss Telephone: 301-443-3865 Email: [email protected] Division of Medications Development Research Joanne B. Fertig, Ph.D. Telephone: 301-443-0635 Email: [email protected] Division of Metabolism and Health Effects Dale Hereld, M.D., Ph.D. Telephone: 301-443-0912 Email: [email protected] Division of Neuroscience and Behavior Lindsey Grandison, Ph.D. Telephone 301-443-0606 Email: [email protected] |
Judy Fox Telephone: 301-443-4704 Email: [email protected] |
| National Institute of Allergy and Infectious Diseases (NIAID) |
As announced in NOT-AI-21-037, NIAID accepts clinical trial applications submitted under PA-20-194 that are not “high-risk”. A “high-risk” clinical trial is defined by NIAID as having one or more of the following attributes:
Applicants proposing “high-risk” clinical trials should not submit to this FOA. Instead applicants proposing “high-risk” clinical trials should refer to NIAID Investigator-Initiated Clinical Trial Resources. Applicants are strongly encouraged to consult the NIAID Scientific/Research Contact listed here prior to submission to confirm the appropriateness of the proposed project for this funding opportunity.
Ellen Goldmuntz, M.D., Ph.D. |
Regina Kitsoulis
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-669-2946 Email: [email protected]
|
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | As announced in NOT-AR-18-008, NIAMS only accepts clinical
trial applications proposing mechanistic studies for the NIH Exploratory/Developmental Research Grant
Program (Parent R21 Clinical Trial Required) (PA-19-054). Applicants who wish to submit clinical trial
applications for consideration by NIAMS should not submit the application to this FOA. Instead,
applicants must submit clinical trial applications to one of the FOAs listed at http://www.niams.nih.gov/Funding/Clinical_Research/clinical_main.asp.
Applicants are strongly advised to consult with NIAMS program staff prior to submitting an application
with human subjects to determine the appropriate funding opportunity. For information regarding NIAMS supported scientific areas/programs and contacts, please see: https://www.niams.nih.gov/grants-funding/supported-scientific-areas. |
Erik Edgerton Telephone: 301-594-7760 Email: [email protected] |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
NICHD Referral Office The NICHD supports research in areas relevant to normal and abnormal human development, including contraception, fertilization, pregnancy, childbirth, prenatal and postnatal development; childhood development through adolescence; intellectual and developmental disabilities; and rehabilitation medicine. https://www.nichd.nih.gov/grants-funding/opportunities-mechanisms/areas-research/Pages/default.aspx. Grant applications and project proposals must fall within the missions of the scientific branches of NICHD's Division of Extramural Research or its National Center for Medical Rehabilitation Research. Potential applicants are strongly encouraged to visit these pages for recent scientific advances and emerging public health topics. If you have questions about projects within a specific research area, you may find an NICHD program officer at https://www.nichd.nih.gov/grants-contracts/research-areas/priorities.
|
Margaret Young Grants Management Branch Telephone: 301-642-4552 Email: [email protected] |
| National Institute on Drug Abuse (NIDA) | Yuki Lama, PhD Phone: 301-443-4577 [email protected] |
Pam Fleming Telephone: 301-480-1159 Email: [email protected] |
| National Institute on Deafness and Other Communication Disorders (NIDCD) | Nancy L. Freeman, Ph.D. Telephone: 301-402-3458 Email: [email protected] For a list of scientific staff, also see Staff Contacts. The National Institute on Deafness and Other Communication Disorders (NIDCD) uses the Exploratory/Developmental Research Grant Award (R21) to support the development of novel ideas, technologies, or methodologies at an early stage of development which have the potential to break new ground or extend toward new directions or applications. The NIDCD supports basic and clinical biomedical and behavioral research in the communication sciences of hearing, balance, smell, taste, voice, speech and language. The proposed research must be focused on one or more of these scientific mission areas. |
Samantha Tempchin Telephone: 301-435-1404 Email: [email protected] |
| National Institute of Environmental Health Sciences (NIEHS) | Bonnie Joubert, Ph.D. Telephone: 984-287-3276 Email: [email protected] https://www.niehs.nih.gov/funding/grants/announcements/index.cfm The National Institute of Environmental Health Sciences (NIEHS) will accept investigator-initiated research projects using the R21 mechanism for all areas of environmental health science research; particularly those defined as NIEHS special emphasis areas. Details on these areas can be found at http://www.niehs.nih.gov/research/supported/programs/index.cfm. To obtain more information about existing NIEHS program areas and their corresponding program administrators, see http://www.niehs.nih.gov/funding/grants/contacts.cfm |
Aaron Nicholas Telephone: 984-287- 3297 Email: [email protected] |
| National Institute on Minority Health and Health Disparities (NIMHD) | The National Institute on Minority Health and Health Disparities (NIMHD) will
accept investigator-initiated exploratory/developmental projects (R21) for all program areas supported
by the Institute. Please click on links below for descriptions of NIMHD’s main research interest areas and contact information for a scientific program contact in each area: Community Health and Population Sciences Clinical and Health Services Research Integrative Biological and Behavioral Sciences |
Priscilla Grant, JD Telephone: 301-594-8412 Email: [email protected] |
| National Institute of Nursing Research (NINR) | The National Institute of Nursing Research (NINR) will accept
investigator-initiated R21 applications for exploratory/developmental projects in areas that are
mission-relevant (http://www.ninr.nih.gov/AboutNINR/NINRMissionandStrategicPlan/).
This includes potentially high-risk/high payoff projects in the early stages of development and projects
having innovative scientific ideas. Please contact the NINR Program Director listed in the area of
science in which you are interested. NINR Program Staff contacts may be found at: http://www.ninr.nih.gov/ResearchAndFunding/ DEA/OEP/AreasofscienceFile.htm |
Brian Albertini Telephone: 301-594-6869 Email: [email protected] |
| National Eye Institute (NEI) |
Dr. Cheri Wiggs
Telephone: 301.402.0276 Email: [email protected] NEI accepts clinical trial applications submitted under PA-20-194 that include human subjects prospectively assigned to one or more interventions that are minimal risk as defined by 45 CFR 46. Minimal risk means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. As part of the review process, the application must include a clear, detailed plan for monitoring safety that is commensurate with the risks to study participants. In addition to the minimal risk designation from the Institutional Review Board, other reporting to the NEI may be required and will be outlined in the Notice of Award Terms and Conditions. Applicants are strongly advised to consult with NEI program staff prior to submitting an
application with human subjects to determine the appropriate funding opportunity announcement.
|
Karen Robinson-Smith Telephone: 301.435.8178 Email: [email protected] |